HR19042 Capsules
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Hepatitis
Conditions
Autoimmune Hepatitis
Trial Timeline
Oct 6, 2022 → Mar 14, 2025
NCT ID
NCT05476900About HR19042 Capsules
HR19042 Capsules is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Autoimmune Hepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05476900. Target conditions include Autoimmune Hepatitis.
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune Hepatitis were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05476900 | Phase 2 | Completed |
Competing Products
20 competing products in Autoimmune Hepatitis